Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40results about How to "Meet the needs of large-scale clinical applications" patented technology

Anti-human C-reactive protein antibody and application thereof

The invention relates to anti-human C-reactive protein (CRP) antibody, a preparation method thereof and application of the antibody in anti-human C-reactive protein detection. An inventor prepares a variety of antibodies, and antibody combinations (P20 and P02) capable of meeting the sensitivity and specificity demands are obtained through pairing and screening. In addition, large-scale production of the antibodies is promoted, and the future large-scale clinic application demand can be met. A colloidal gold immunochromatography quantitative determination card simple and convenient to operate and having sensitivity, specificity and relevant detection properties capable of meeting human clinic sample detection, of a detected human C-reactive protein can be obtained through the detection system debugging and optimizing work to the antibody combinations.
Owner:ZONHON BIOPHARMA INST

Anti-human CD26 antibody and application of anti-human CD26 antibody in detection kit

The invention relates to an anti-human CD26 antibody, and preparation and a commercial application of the anti-human CD26 antibody, and belongs to the field of in vitro diagnosis. A heavy chain variable region of the anti-human CD26 antibody comprises the following complementarity-determining regions: HCDR1 with an amino acid sequence shown as SEQ ID NO: (sequence identifier number) 1, HCDR2 withan amino acid sequence shown as SEQ ID NO: 2, and HCDR3 with an amino acid sequence shown as SEQ ID NO: 3; and a light chain variable region of the anti-human CD26 antibody comprises the following complementarity-determining regions: LCDR1 with an amino acid sequence shown as SEQ ID NO: 4, LCDR2 with an amino acid sequence shown as SEQ ID NO: 5, and LCDR3 with an amino acid sequence shown as SEQ ID NO: 6. Relevant detection performance, such as specificity, of the anti-human CD26 antibody can meet performance requirements of an immunohistochemical kit; and a chimeric humanized antibody constructed by the applicant on a basis of the antibody is more convenient to recombine, express and produce massively, reduces a human anti-mouse antibody response and non-specific adsorption and can meet requirements of large-scale clinical application.
Owner:ZONHON BIOPHARMA INST

Fluorogenic quantitative detection test card for human C-reactive protein

The invention relates to anti-human C-reactive protein antibody and application thereof. The invention prepares a plurality of antibodies, and performs pairing and screening to obtain the antibody combination (P24 and P03) with which sensitivity and specificity can satisfy the requirement. The antibody is convenient to produce in large quantities, and can meet the requirement of clinical application in large-scale. The time-resolved fluoroimmunoassay chromatography quantitative detection card of human C-reactive protein having meeting clinical sample detection performances such as sensitivity, specificity and related detection performance is obtained by means of adjusting and optimizing of detection system for the antibody combination, and the detection card is easy and simple to operate.
Owner:江苏晶红生物医药科技股份有限公司

Test paper card for fluorescent quantitative detection of human PCT (procalcitonin)

The invention relates to a test paper card for fluorescent quantitative detection of human PCT (procalcitonin). According to the invention, various antibodies are prepared and subjected to pairing screening, and an antibody combination with sensitivity and specificity both meeting requirements is obtained; mass production of the test paper card is facilitated, and the requirement for large-scale clinical application in the future can be met. The antibody combination is subjected to a debugging and optimizing work of a detection system, the time-resolved immunofluorescence chromatography quantitative detection card which is simple and convenient to operate and applied to the human PCT is obtained, and the sensitivity, the specificity and related detection performance of the card can meet the requirements of human clinical sample detection.
Owner:江苏晶红生物医药科技股份有限公司

ELISA quantitative detection kit for human tissue kallikrein 1

The invention relates to an ELISA quantitative detection kit for detecting human tissue kallikrein 1 (hK1) and related antibodies. According to the invention, a plurality of monoclonal antibodies are prepared and are paired and screened, so an antibody combination (A24 and A32) with sensitivity and specificity meeting demands is obtained; and the antibody combination can be conveniently produced in a large scale and can meet demands of large-scale clinical application in the future. The antibody combination is subjected to adjustment and optimization of a detection system so as to obtain the ELISA quantitative detection kit for human tissue kallikrein 1 with the advantages of simple operation and good sensitivity, specificity and related detection performance.
Owner:ZONHON BIOPHARMA INST

Immunohistochemical detection kit for human CD26 and clinical application thereof

The invention, which belongs to the field of in vitro diagnosis, relates to an immunohistochemical detection kit for human CD26 and clinical application thereof. According to the disclosed immunohistochemical detection kit, a novel anti-human-CD26 antibody is employed; the heavy chain variable region contains following complementarity determining regions: HCDR1, HCDR2, and HCDR3 having the amino acid sequences shown by SEQ ID NO:1, 2, and 3 respectively; and light chain variable region sequences contain following complementarity determining regions: LCDR1, LCDR2, LCDR3 having the amino acid sequences shown by SEQ ID NO:4, 5, 6. According to the invention, the performance requirement of the immunohistochemical kit can be met by related detection performances like the specificity of the anti-human-CD26 antibody; the antibody can be a mouse antibody or a recombinantly expressed chimeric human antibody and is convenient to product in a large scale; with the recombinantly expressed chimerichuman antibody, the human anti-mouse antibody response is reduced and the non-specific adsorption is reduced; and thus the need of large-scale clinical application can be met. In the application of the CD26 target drug, the effect of precise treatment is realized by using the immunohistochemical detection kit.
Owner:ZONHON BIOPHARMA INST

A kind of anti-human cd26 antibody and its application in detection kit

The invention relates to an anti-human CD26 antibody, and preparation and a commercial application of the anti-human CD26 antibody, and belongs to the field of in vitro diagnosis. A heavy chain variable region of the anti-human CD26 antibody comprises the following complementarity-determining regions: HCDR1 with an amino acid sequence shown as SEQ ID NO: (sequence identifier number) 1, HCDR2 withan amino acid sequence shown as SEQ ID NO: 2, and HCDR3 with an amino acid sequence shown as SEQ ID NO: 3; and a light chain variable region of the anti-human CD26 antibody comprises the following complementarity-determining regions: LCDR1 with an amino acid sequence shown as SEQ ID NO: 4, LCDR2 with an amino acid sequence shown as SEQ ID NO: 5, and LCDR3 with an amino acid sequence shown as SEQ ID NO: 6. Relevant detection performance, such as specificity, of the anti-human CD26 antibody can meet performance requirements of an immunohistochemical kit; and a chimeric humanized antibody constructed by the applicant on a basis of the antibody is more convenient to recombine, express and produce massively, reduces a human anti-mouse antibody response and non-specific adsorption and can meet requirements of large-scale clinical application.
Owner:ZONHON BIOPHARMA INST

Immunohistochemical detection kit for human cd26 and its clinical application

The invention relates to an immunohistochemical detection kit for human CD26 and its clinical application, belonging to the field of in vitro diagnosis. The immunohistochemical detection kit disclosed in the present invention adopts a brand-new anti-human CD26 antibody, and its heavy chain variable region contains the following complementarity determining regions: the amino acid sequences are as shown in SEQ ID NO: 1, 2, 3 respectively HCDR1, HCDR2, HCDR3; and their light chain variable region sequences contain the following complementarity determining regions: LCDR1, LCDR2, LCDR3 shown in SEQ ID NO: 4, 5, 6, respectively. The specificity of the anti-human CD26 antibody used in the present invention can meet the performance requirements of the immunohistochemical kit, and it can be a mouse antibody or a recombinantly expressed chimeric human antibody, which is convenient for mass production, wherein the recombinantly expressed chimeric antibody Combined with human antibodies to reduce human anti-mouse antibody reactions and non-specific adsorption, it can also meet the needs of large-scale clinical applications. When using the CD26 target drug, the immunohistochemical kit of the present invention can be used together to achieve the effect of precise treatment.
Owner:ZONHON BIOPHARMA INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products